

P1157 REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA

Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

Bijal Shah¹, Keri Yang², Andrew Klink³, Tom Liu², Todd Zimmerman², Ajeet Gajra³, Boxiong Tang²

¹ H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States; ² Beigene USA, San Mateo, United States; ³ Cardinal Health, Dublin, United States

Background: Bruton tyrosine kinase inhibitor (BTKi) therapies, approved for relapsed or refractory (R/R) mantle cell lymphoma (MCL), have not been comprehensively evaluated in real world populations.

Aims: This study aimed to assess patient characteristics, treatment patterns and associated outcomes in real world BTKi-treated MCL patients.

Methods: The retrospective multicenter chart review was conducted in the Cardinal Health Oncology Provider Extended Network. EMR data were extracted for eligible patients diagnosed with MCL who initiated any of the approved BTKi (ibrutinib, acalabrutinib, zanubrutinib) from 2018 to 2021; patients enrolled in trials were excluded. Index date was defined as the use of any of the BTKis. Patients were required to have 12-month pre-index for medical history, and from index to last follow-up or death. Descriptive analyses were conducted to assess demographic/clinical characteristics, MCL baseline features, BTKi treatment patterns, adverse events (AE), and response rates by BTKi. Multivariable logistic regression was performed to assess factors associated with response and AE.

Results: The study cohort consisted of 300 MCL patients (59% male; 69% white); most (64%) patients were covered by Medicare, 34% had commercial insurance. BTKis were given mainly as monotherapy (93%) and in R/R setting (86%). Patients in zanubrutinib group were significantly older (n = 100, median age = 71, range = 50-91) than patients in ibrutinib (n = 100, median age = 69, range = 39-87) and acalabrutinib (n = 100, median age = 70, range = 51-86) groups. Significantly fewer patients in the zanubrutinib group had baseline Ann Arbor stage I-II (4%) than ibrutinib (10%) or acalabrutinib (13%), while more zanubrutinib patients had presence of B symptoms (67%) than ibrutinib (44%) or acalabrutinib (57%). Patients in the zanubrutinib group also had significantly less with ECOG of 3+ (4%) compared to ibrutinib (8%) or acalabrutinib (6%). At BTKi initiation, significantly more patients in zanubrutinib group (18%) had history of atrial fibrillation than ibrutinib (1%) or acalabrutinib (5%). BTKis were given mainly as second-line (86%) and as monotherapy (93%). Most patients were started at an on-label BTKi dose. In zanubrutinib patients, the dose of 160 mg BID was more commonly administered (64%) than 320 mg QD (31%). Multivariable regression reported a significant association of age, gender, extranodal/splenic involvement, and timing of BTKi initiation with response and AE (Table).

Image:

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

	Response	AE
	Odds Ratio (95% Confidence Interval)	
BTKi		
Zanubrutinib	Reference	Reference
Ibrutinib	0.75 (0.38, 1.47)	1.17 (0.61, 2.24)
Acalabrutinib	0.87 (0.45, 1.69)	1.52 (0.80, 2.87)
Age	0.54 (0.31, 0.96)*	2.52 (1.43, 4.47)*
Gender		
Male	Reference	Reference
Female	0.91 (0.84, 0.98)*	0.96 (0.92, 1.01)
RACE		
White	Reference	Reference
Non-White	1.11 (0.63, 1.94)	1.44 (0.84, 2.46)
Ann Arbor stage		
2+	Reference	Reference
0/1	1.04 (0.57, 1.91)	0.70 (0.40, 1.22)
ECOG		
2+	Reference	Reference
0/1	0.31 (0.07, 1.43)	0.69 (0.27, 1.72)
Splenic involvement		
Yes	Reference	Reference
No	0.34 (0.19, 0.60)*	0.49 (0.28, 0.86)*
Extranodal disease involvement		
Yes	Reference	Reference
No	0.33 (0.16, 0.68)*	0.31 (0.14, 0.68)*
BTKi line of therapy		
2L+	Reference	Reference
1L	0.73 (0.25, 2.16)	0.26 (0.01, 0.70)*

*P value <0.05

Summary/Conclusion: This study provides the first real world evidence on comparative effectiveness of ibrutinib, acalabrutinib, and zanubrutinib in MCL patients. While patients treated with zanubrutinib were older and had more complex MCL baseline features at initiation, multivariable regression suggested a trend favoring zanubrutinib over ibrutinib or acalabrutinib for both response and AE. Frontline initiation of BTKi therapy was also associated with improved tolerability. Future real world studies are needed to discern long-term outcomes.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.